Detailed price information for Gyre Therapeutics Inc (GYRE-Q) from The Globe and Mail including charting and trades.

Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 ...

Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in ...

Get all latest & breaking news on Nishith Desai Associates. Watch videos, top stories and articles on Nishith Desai Associates at moneycontrol.com.

GEE Group Inc. (NYSE American:JOB) together with its subsidiaries (collectively referred to as the "Company," "GEE Group," ...

Family offices are increasingly turning to private secondary market transactions to gain exposure to sought-after companies ...

A bill to end non-disclosure agreements that prevent victims from talking about sexual abuse appears to be on its way to becoming law in Alabama. Trey’s Law was inspired by the story of Trey Carlock ...

The $4.00 per share cash offer price represents an approximate 85% premium and, including both CVRs, an approximate 180% premium to Lisata’s most recent closing stock price and reflects the strategic ...

The FDA has accepted a New Drug Application (NDA) for Celcuity’s gedatolisib in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2), PIK3CA wild-type advanced ...

QRX003 has received Orphan Drug and Pediatric Rare Disease Designations from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency for the potential ...

FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026MINNEAPOLIS, (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: ...